Anti-Adenovirus ELISA (IgG)
Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
EI 2680-9601 G	Adenovirus	IgG	Ag-coated microplate wells	96 x 01 (96)

Principles of the test: The ELISA test kit provides a semiquantitative or quantitative in vitro assay for human antibodies of the IgG class against adenovirus in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with adenovirus antigens. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies (also IgA and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells, coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	STRIPS
2. Calibrator 1 200 RU/ml (IgG, human), ready for use	dark red	1 x 2.0 ml	CAL 1
3. Calibrator 2 20 RU/ml (IgG, human), ready for use	red	1 x 2.0 ml	CAL 2
4. Calibrator 3 2 RU/ml (IgG, human), ready for use	light red	1 x 2.0 ml	CAL 3
5. Positive control (IgG, human), ready for use	blue	1 x 2.0 ml	POS CONTROL
6. Negative control (IgG, human), ready for use	green	1 x 2.0 ml	NEG CONTROL
7. Enzyme conjugate peroxidase-labelled anti-human IgG (rabbit), ready for use	green	1 x 12 ml	CONJUGATE
8. Sample buffer ready for use	light blue	1 x 100 ml	SAMPLE BUFFER
9. Wash buffer 10x concentrate	colourless	1 x 100 ml	WASH BUFFER 10x
10. Chromogen/substrate solution TMB/H_2O_2, ready for use	colourless	1 x 12 ml	SUBSTRATE
11. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	STOP SOLUTION
12. Test instruction	---	1 booklet	
13. Protocol with target values	---	1 protocol	
LOT Lot IVD In vitro determination	CE		Storage temperature Unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents are to be disposed of according to official regulations.

Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
  Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for a minimum of 4 months.

- **Calibrators and controls:** Ready for use. The reagents must be mixed thoroughly before use.

- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.

- **Sample buffer:** Ready for use.

- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallisation occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionised or distilled water (1 part reagent plus 9 parts distilled water).
  For example, for 1 microplatestrip: 5 ml concentrate plus 45 ml water.
  The ready-to-use diluted wash buffer is stable for 1 month when stored at +2°C to +8°C and handled properly.

- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.

- **Stop solution:** Ready for use.

Warning: The control sera used have been tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid skin contact.

Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: Patient samples are diluted **1:101** in sample buffer. For example: dilute 10 µl serum in 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

NOTE: Calibrators and controls are prediluted and ready for use, do not dilute them.

Incubation

For **semiquantative analysis** incubate **calibrator 2** along with the positive and negative controls and patient samples. For **quantitative analysis** incubate **calibrators 1, 2 and 3** along with the positive and negative controls and patient samples.

Sample incubation: (1. step)
Transfer 100 µl of the calibrators, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol.
Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:
Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.
Automatic: Wash reagent wells 3 times with 450 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer “Overflow Modus”).

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to false high extinction values.
Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2. step)
Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) into each of the microplate wells.
Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:
Empty the wells. Wash as described above.

Substrate incubation: (3. step)
Pipette 100 µl of chromogen/substrate solution into each of the microplate wells.
Incubate for **15 minutes** at room temperature (+18°C to +25°C) (protect from direct sunlight).

Stopping the reaction:
Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:
Photometric measurement of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength of between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the micro-plate to ensure a homogeneous distribution of the solution.

Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	**C**	**P 6**	**P 14**	**P 22**			**C 1**	**P 4**	**P 12**	**P 20**		
B	**pos.**	**P 7**	**P 15**	**P 23**			**C 2**	**P 5**	**P 13**	**P 21**		
C	**neg.**	**P 8**	**P 16**	**P 24**			**C 3**	**P 6**	**P 14**	**P 22**		
D	**P 1**	**P 9**	**P 17**				**pos.**	**P 7**	**P 15**	**P 23**		
E	**P 2**	**P 10**	**P 18**				**neg.**	**P 8**	**P 16**	**P 24**		
F	**P 3**	**P 11**	**P 19**				**P 1**	**P 9**	**P 17**			
G	**P 4**	**P 12**	**P 20**				**P 2**	**P 10**	**P 18**			
H	**P 5**	**P 13**	**P 21**				**P 3**	**P 11**	**P 19**			

The pipetting protocol for microtiter strips 1-4 is an example for the **semiquantitative analysis** of 24 patient samples (P 1 to P 24).
The pipetting protocol for microtiter strips 7-10 is an example for the **quantitative analysis** of 24 patient samples (P 1 to P 24).

The calibrators (C 1 to C 3), the positive (pos.) and negative (neg.) controls, and the patient samples have each been incubated in one well. The reliability of the ELISA test can be improved by duplicate determinations for each sample.
The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimises reagent wastage.
Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of the calibrator 2. Calculate the ratio according the following formula:

$$\frac{\textbf{Extinction of the control or patient sample}}{\textbf{Extinction of calibrator 2}} = \textbf{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	**negative**
Ratio ≥0.8 to <1.1:	**borderline**
Ratio ≥1.1:	**positive**

In cases of borderline test results, an additional patient sample should be taken 7 days later and re-tested in parallel with the first patient sample. The results of both samples allow proper evaluation of titer changes.

Quantitative: The standard curve from which the concentration of antibodies in the patient samples can be taken is obtained by point-to-point plotting of the extinction values measured for the 3 calibration sera against the corresponding units (linear/linear). Use “point-to-point” plotting for calculation of the standard curve by computer. The following plot is an example of a typical calibration curve. Please do not use this curve for the determination of antibody concentrations in patient samples.



If the extinction of a serum sample lies above the value of calibrator 1 (200 RU/ml). The result shold be given as ">200 RU/ml". It is recommended that the sample be re-tested at a dilution of 1:400. The result in RU/ml read from the calibration curve for this sample must then be multiplied by a factor of 4.

The upper limit of the normal range of non-infected persons (**cut-off value**) recommended by EUROIMMUN is **20 relative units (RU)/ml**. EUROIMMUN recommends interpreting results as follows:

<16 RU/ml:	**negative**
≥16 to <22 RU/ml:	**borderline**
≥22 RU/ml:	**positive**

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account alongside the serological results.

Test characteristics

Calibration: As no international reference serum exists for antibodies against adenovirus, the calibration is performed in relative units (RU).

For every group of tests performed, the extinction values of the calibrators and the relative units and/or the ratios determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A protocol containing these target values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature during substrate incubation, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibration sera are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigen: The antigen source is provided by cell lysates of MRC-5 cells infected with the "Adenoid 6" strain of adenovirus.

Linearity: The linearity of the test was investigated using series dilutions of patient sera with high antibody concentrations. The Anti-Adenovirus ELISA (IgG) is linear in the measurement range 2-200 RU/ml.

Detection limit: The detection limit is defined as a value of three times the standard deviation of an analyte-free sample and is the smallest detectable antibody titer. The lower detection limit of the Anti-Adenovirus ELISA (IgG) is 1 RU/ml.

Cross reactivity: This ELISA showed no cross reactivity.

Interference: Haemolytic, lipaemic and icteric samples showed no influence at the result up to a concentration of 10 mg/ml for haemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

Intra-Assay Variation, n = 20		
Serum	**Mean value (RU/ml)**	**CV (%)**
1	80	5.8
2	99	5.3
3	105	5.9

Inter-Assay Variation, n = 4 x 6		
Serum	**Mean value (RU/ml)**	**CV (%)**
1	76	8.0
2	94	10.3
3	105	7.7

Reference range: The levels of the anti-Adenovirus antibodies (IgG) were analysed with this EUROIMMUN ELISA in a panel of 300 healthy blood donors. With a cut-off of 20 RU/ml, 64.3% of the blood donors were anti-Adenovirus positive (IgG) which reflects the known percentage of infections in adults.

Clinical significance

Adenoviruses, which are pathogenic for humans, belong to the Adenoviridae family and are non-enveloped viruses with a double-stranded, linear DNA as their genome [1, 2]. They were first isolated from human tonsils and other adenoid tissue and propagated in a cell culture in 1953 by a group of scientists under the direction of W. P. Rowe [1, 3]. Adenoviruses have a high stability against chemical and physical influences and a high tolerance for extreme pH-values and alcoholic disinfectants. The viruses can be fully inactivated by heating to 56°C for 10 minutes. Today, six human-pathogenic adenovirus types are known (human adenovirus A to F), which are again divided into a total of 51 serologically distinguishable subtypes [1, 4, 5]. The way of genetic transmission within the host cell is known to a large extent [2, 6, 7, 8, 9, 10].

Adenoviruses are transmitted by direct contact, faecal-orally and, occasionally, through water [1, 3] They are the main cause of respiratory diseases. Spreading of the virus can take several months or years [9, 11]. The symptoms of respiratory diseases caused by adenoviruses range from common colds over bronchitis to pneumonia. Patients with a weakened immune system are particularly prone to develop severe complications of adenovirus infections, e.g. ARDS (acute respiratory distress syndrome) [9]

Some virus types cause persisting asymptomatic infections of the palatine and pharyngeal tonsils or the gastrointestinal tract [4]. Various other diseases, e.g. gastroenteritis, conjunctivitis, cystitis, rhinitis, pharyngitis or diarrhoea may occur depending on the serotype [4]. The serotypes 1, 2, 5 and 6 are endemic in some regions throughout the world [8]. Infection generally occurs during childhood [12]. Serotypes 8, 19 and 37 cause epidemic ceratoconjunctivitis [13]. Adenovirus types 1 to 39 are involved worldwide in about 6% of infections of the respiratory tract [14]. Types 40 and 41 can cause gastroenteritis, in this respect taking the second place after rotaviruses for small children [1, 4, 8, 12, 13].

Manifestations such as persisting bronchiolitis, dilatative cardiomyopathy, type-1 diabetes or hearing loss are discussed as late manifestations of the infection [13]. A connection between virus type Ad-36 and adipositas in humans is also considered [10, 13, 15].

Most of the adenovirus infections have a mild course and do not require therapy but merely treatment of the symptoms. Due to a lack in virus-specific therapy, even in severe cases treatment is largely aiming at reducing the symptoms and complications of the infections [16].

Vaccines had been developed for serotypes 4 and 7, however, they were only available until 1998 for the prevention of severe respiratory infections in recruits of the US Army [16, 17]. There are no vaccines available for the general public. Therefore, effectively preventing the adenovirus associated infections from spreading can only be achieved by careful infection control [7].

For the detection of acute and chronic adenovirus infections electron microscopy and serology are used [4]. Specific class IgA (IgG and IgM) antibodies can be found in the serum [14].

Literature references

1. Wiegand R. **Adenoviren.** In: Brandis H, Köhler W, Eggers HJ, Pulverer G. (eds) Medizinische Mikrobiologie. Gustav Fischer Verlag Stuttgart, Jena, New York (1994).
2. Mathews MB, Shenk T. **Adenovirus virus-associated RNA and translational contro**l. Journal of Virology 65 (1991) 5657-5662.
3. Horwitz MS. **Adenoviridae and their replication.** In: Fields BN (ed) Virology 2nd Ed. Raven Press New York (1990) 1723-1742.
4. Wadell G, Allard A, Johannsson M, Svensson L, Uhnoo J. **Enteric adenoviruses.** Ciba Found Symp 128 (1987) 63-91.
5. Adrian T, Sassinek J, Wigand R. **Genome type analysis of 480 isolates of adenovirus types 1, 2, and 5.** Arch Virol 112 (1990) 235-248.
6. Fauquet CM, Fargette D. **International Committee on Taxonomy of Viruses and the 3,142 unassigned species.** Virol J. 2005; 2: 64.
7. Horwitz MS, Sarvetnick N. **Viruses, host responses, and autoimmunity.** Immunol Rev 169 (1999) 241-253.
8. Pring-Akerblom P, Adrian T. **Sequence characterization of the adenovirus 31 fibre and comparison with serotypes of subgenera A to F.** Res Virol 146 (1995) 343-354.
9. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jeffrrries WA, Hogg JC. **Latent adenoviral infection in the pathogenesis of chronic airways obstruction.** Am Rev Respir Dis 146 (1992) 177-184.
10. Rathod M, Vangipuram SD, Krishnan B, Heydari AR, Holland TC, Dhurandhar NV. **Viral mRNA expression but not DNA replication is required for lipogenic effect of human adenovirus Ad-36 in preadipocytes.** Int J Obes (Lond) 2006 May 2 [Epub ahead of print].
11. Schmitz H, Wigand R, Heinrich W. **Worldwide epidemiology of human adenovirus infections.** Am J Epid 117 (1983) 455-466.
12. Saderi H, Roustai MH, Sabahi F, Sadeghizadeh M, Owlia P, De Jong JC. **Incidence of enteric adenovirus gastroenteritis in Iranian children.** J Clin Virol 24 (2002) 1-5.
13. Makela M, Vaarala O, Hermann R, Salminen K, Vahlberg T, Veijola R, Hyoty H, Knip M, Simell O, Ilonen J. **Enteral virus infections in early childhood and an enhanced type 1 diabetes-associated antibody response to dietary insulin.** J Autoimmun 27 (2006) 54-61.
14. Chkhaidze I, Manjavidze N, Nemsadze K. **Serodiagnosis of acute respiratory infections in children in Georgia.** Indian J Pediatr 73 (2006) 569-572.
15. Vangipuram SD, Yu M, Tian J, Stanhope KL, Pasarica M, Havel PJ, Heydari AR, Dhurandhar NV. **Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells.** Int J Obes (Lond) 2006 May 16 [Epub ahead of print].
16. Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, Hansen CJ, Gray GC, Gaydos JC. **Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.** Vaccine 24 (2006) 2835-2842.

17. Howell MR, Nang RN, Gaydos CA, Gaydos JC. **Prevention of adenoviral acute respiratory disease in Army recruits: cost-effectiveness of a military vaccination policy.** Am J Prev Med 14 (1998) 168-175.